V5med

What V5med does

V5med Inc. is a Taiwan-based AI medical imaging company headquartered in the Hsinchu Science Industrial Park and operating as a subsidiary of V5 Technologies, a semiconductor optical-inspection and AI firm founded in 2014 by Dr. Kun-Si Lin, a former Senior Vice President of TSMC. Established in 2016, V5med applies the parent's high-speed imaging and computer-vision algorithms—originally developed for nanometer-scale wafer defect detection—to the analysis of low-dose CT (LDCT) scans for lung cancer screening. The company's core product, V5 Lung AI (model V5-MED-LU01), is a computer-aided detection system that automatically annotates pulmonary nodules, ground-glass opacities, and other findings from a single LDCT scan, providing real-time measurements, Lung-RADS classification, longitudinal volume doubling time tracking, and structured reporting per ACR Lung-RADS and Fleischner guidelines. Reported performance includes 95.6% overall sensitivity for pulmonary nodule detection, 92.8% sensitivity for 4–5mm nodules, and 95.7% sensitivity for GGO nodules. The complementary V5 AI Conductor Platform enables multi-AI deployment and PACS integration across the top three Taiwan PACS systems.

V5med's regulatory profile includes Taiwan FDA (TFDA) Class II certification obtained in November 2022—the first AI-based medical device license for pulmonary nodule detection in Taiwan—U.S. FDA 510(k) clearance in March 2025 (the first such clearance for a Taiwanese LDCT lung cancer screening AI), and ISO 13485 and GMP certifications from 2020. The product is vendor-neutral and PACS/HIS-integrated, with deployment modalities spanning on-premise and cloud, supporting compatibility with all major CT scanner brands. The portfolio has expanded beyond the flagship lung CT module to include pathology (V5Lung-Cyto), cardiac (AccuCardio), pulmonary (AccuPulmo), medical image digitization (V5 MIDI), spine (V5 Spine-X), and an integrated Multi-stage Smart Imaging-Assisted Lung Cancer Clinical Diagnosis Accelerator developed jointly with Taipei Veterans General Hospital.

V5med monetizes through SaaS/subscription licensing of its diagnostic software to hospitals and medical imaging centers, combined with international licensing via exclusive distribution partnerships. Domestically, V5med engages large hospital systems (including Taipei Veterans General Hospital, NTU Hsinchu Branch, Taichung Veterans General Hospital, and Chung Shan Medical University Hospital) through direct enterprise sales and government tenders (e.g., 8 of 12 private-hospital contracts in the Taoyuan City lung cancer screening program). Internationally, the company operates through exclusive distribution agreements—notably a 5-year Thailand agreement with SaintMed (monthly subscription rental model, signed September 2023), an exclusive Japan alliance with Clairvo Technologies (April 2024), and distribution MOUs in Singapore, Malaysia, Vietnam, Indonesia, India, Brazil, and the United States. Within two years of TFDA approval, the system was adopted by 40+ Taiwan hospitals, and 13 distributors across 9 countries were signed. Strategic partners include AstraZeneca Taiwan, with whom V5med signed a May 2024 MOU to jointly promote AI-assisted lung cancer screening. Recognition includes the 2022 Taipei Biotech Award (Cross-Disciplinary Integration), Hsinchu Science Park Bureau Innovative Product of the Year, National Innovation Award (Clinical Innovation), and the 2024 NHQA National Medical Quality Award Bronze Medal.

Name

V5med

Legal name

V5med Inc.

Website

https://v5med.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

V5med Inc. is a Taiwan-based AI medical imaging company that develops FDA-cleared and TFDA-certified computer-aided detection software for low-dose CT lung cancer screening, serving hospitals and medical centers across Taiwan, Thailand, Japan, Indonesia, and other international markets.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software (Lung Cancer Screening)

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Health Services (8000)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI), Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• AI medical imaging
• Lung cancer screening
• Computer-aided detection
• Radiology AI software
• Low-dose CT analysis

Headquarters

HQ city

Hsinchu

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI Diagnostic Software Licenses (Subscription/SaaS): V5med generates revenue through licensing its FDA/TFDA-cleared V5 Lung AI software to hospitals and medical imaging centers. The Thailand distributor SaintMed uses a monthly subscription rental model offered to hospitals. In Taiwan, the company serves hospitals directly. Revenue from the smart healthcare division was expected to grow significantly following TFDA certification in late 2022 and FDA clearance in March 2025.
2. International Distribution and Licensing: V5med licenses its technology to international distributors and partners for deployment in their respective markets. Partnerships include exclusive distribution agreements (Thailand, 5-year) and regulatory collaboration (Japan with Clairvo Technologies). The company had secured distribution MOUs or agreements in 8 countries as of early 2023.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

V5med develops and licenses AI-powered medical imaging software for lung cancer screening on low-dose CT (LDCT) scans. Its flagship V5 Lung AI (V5-MED-LU01) automatically detects, measures, classifies, and longitudinally tracks pulmonary nodules—including ground-glass opacities—with 95.6% overall sensitivity, and generates structured reports aligned with ACR Lung-RADS and Fleischner guidelines. The software is FDA 510(k)-cleared, TFDA-certified, PACS-integrated, vendor-neutral, and sold to hospitals, medical centers, and national cancer screening programs via direct enterprise sales in Taiwan and exclusive distributor/partner channels in Thailand, Japan, Indonesia, and other markets.

Product overview

V5med offers an AI-powered diagnostic platform centered on V5 Lung AI as the core product, complemented by the V5 AI Conductor Platform for integration and multi-AI deployment. The product portfolio includes specialized modules: AccuCardio for cardiac imaging, AccuPulmo for pulmonary imaging, V5Lung-Cyto for lung cell pathology analysis, V5 MIDI for medical image digitalization, and V5 Spine-X for spine evaluation. The company also offers the Multi-stage Smart Imaging-Assisted Lung Cancer Clinical Diagnosis Accelerator that integrates V5 Lung AI with automated microscopy and AI cell analysis. All products are designed for clinical deployment in hospital settings, with PACS/HIS integration capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• V5med Lung AI: FDA-cleared AI-powered computer-aided detection system for low-dose CT lung cancer screening, supporting rapid detection and evaluation of pulmonary nodules with real-time measurements and Lung-RADS classification.
• V5 AI Conductor Platform
• 倍智醫電

Products and services

• V5 Lung AI (V5-MED-LU01) FDA 510(k)-cleared and TFDA-certified AI computer-aided detection (CADe) system for low-dose CT lung cancer screening. Automatically detects, annotates, and measures pulmonary nodules (including 4–30mm and GGO nodules) with 95.6% overall sensitivity, supports Lung-RADS classification, longitudinal volume doubling time tracking, and generates structured reports per ACR Lung-RADS and Fleischner guidelines. PACS-integrated, vendor-neutral, and compatible with all major CT scanner brands. Used by radiologists and hospital lung cancer screening programs.
• V5 AI Conductor Platform Taiwan's first multi-AI clinic integration platform that enables deployment of multiple AI modules within a single clinical operation. Integrates with the top three Taiwan PACS systems, supports DICOM data query/upload/download, marker drawing, AI big data database with remote database capability, online and offline AI inference. Designed for hospital radiology departments and IT teams deploying AI at scale.
• AccuCardio AI solution for cardiac imaging analysis, part of V5med's intelligent medical care AI imaging portfolio for use in hospital radiology and cardiology workflows.
• AccuPulmo AI solution for pulmonary imaging analysis, part of V5med's intelligent medical care AI imaging portfolio for use alongside V5 Lung AI in hospital pulmonary and radiology workflows.
• Multi-stage Smart Imaging-Assisted Lung Cancer Clinical Diagnosis Accelerator Integrated multi-stage lung cancer diagnosis solution combining V5 Lung AI with automated microscopy and AI-assisted cancer region marking and cell classification counting, designed to accelerate lung cancer diagnosis across thoracic surgery, radiology, and pathology departments. Available to hospitals seeking a coordinated radiology-pathology AI workflow.
• V5Lung-Cyto (Lung Cancer Cell Pathology AI) AI-powered lung cancer cell pathology analysis system performing automated cancer region detection and cell classification counting under microscopy for hospital pathology departments.
• V5 MIDI (Medical Image Digitalization) Medical image digitalization solution for hospital image workflows, part of the V5med intelligent medical platform portfolio.
• V5 Spine-X (Spine Evaluation) AI-assisted automated spine evaluation system for assessment of spinal conditions, offered to hospital radiology and orthopedic departments.

Quantifiable outcome

• 95.6% overall sensitivity for pulmonary nodule detection; 92.8% for 4–5mm nodules; 95.7% for GGO nodules
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core, major and minor.

• AstraZeneca TaiwancoreStrategic or Co-development Partner · 6 May 2024V5med and AstraZeneca Taiwan signed a memorandum of understanding to jointly promote AI-assisted lung cancer early screening. The partnership aims to enhance screening quality for high-risk populations (individuals with family history of lung cancer and heavy smokers), facilitate early intervention, and strengthen the lung cancer prevention and treatment network. AstraZeneca runs the 'Doubling Lung Cancer Survival Advocacy Platform' targeting a doubling of Taiwan's 5-year survival rate by 2025, with over 1,000 lung cancers detected, 85% at early stage.
• Clairvo Technologies Co., Ltd. (Japan)coreChannel Partner/ Reseller/ Distributor · 17 April 2024V5med entered an exclusive business alliance agreement with Clairvo Technologies (Tokyo, CEO: Riichi Yamada) for chest CT imaging diagnostic support software. The partnership aims to obtain regulatory approvals and market the product in Japan. The V5med product has TFDA Class II certification and assists in detection of nodules in low-dose CT images, providing location, size, volume, and characteristics. The report generation support function contributes to efficiency of image reading.
• Dharmais National Cancer Hospital (Indonesia)majorStrategic or Co-development Partner · 15 December 2023Dharmais National Cancer Hospital (Indonesia's national referral cancer center) conducted a pilot clinical study using V5med's AI system and presented results at the 1st Annual Indonesian Cancer Conference (December 2023). The study demonstrated high sensitivity and accuracy in identifying early-stage lung nodules, supporting Indonesia's national cancer early diagnosis strategy.
• SaintMed Public Company Limited (Thailand)coreChannel Partner/ Reseller/ Distributor · 25 September 2023SaintMed signed an exclusive 5-year distribution agreement for V5med's lung cancer AI detection system in Thailand (signed September 25, 2023). The agreement covers CT images from all scanner brands. SaintMed offers the product to Thai hospitals on a monthly subscription rental basis, generating recurring income. SaintMed is undergoing a business transformation from traditional trading to recurring revenue models (leasing, revenue-sharing, installment purchases).
• Taichung Veterans General Hospital (台中榮民總醫院)coreStrategic or Co-development Partner · 1 February 2023Taichung VGH signed an MOU with V5med to accelerate AI implementation and commercialization of smart healthcare solutions. Taichung VGH was ranked among the Top 300 Smart Hospitals Worldwide in 2023 (the only Chinese-speaking hospital on the list) and is the #1 hospital in AI development across Greater China. The hospital has over 100 AI models under development. V5med's role is to provide industry-proven experience in large-scale AI model deployment.
• Taiwan Lung Cancer Society / Intel / World Peace International GroupminorStrategic or Co-development Partner · 24 October 2022Co-hosted the 'Lung Cancer Diagnosis and AI Application Symposium' in October 2020 with the Taiwan Lung Cancer Society, Intel, and World Peace International Group. Also co-sponsored the Taiwan Chest Surgery Society Forum with AstraZeneca in July 2023.
• National Taiwan University Hospital Hsinchu Branch (國立台灣大學醫學院附設醫院新竹臺大分院)majorStrategic or Co-development Partner · 9 June 2021Signed MOU in June 2021 to jointly promote precision smart healthcare using V5med's lung imaging AI. NTU Hsinchu Branch deployed the V5 Lung AI platform to assist physicians in faster lung nodule reading, reduced errors, and more precise clinical services.
• Taipei Veterans General Hospital (台北榮民總醫院)coreStrategic or Co-development Partner · 24 September 2020V5med has an ongoing strategic collaboration with Taipei VGH dating back to 2020. Taipei VGH conducted early clinical validation studies for V5med's lung nodule AI system and was the first hospital to establish an AI-assisted lung nodule clinic. V5med and Taipei VGH jointly developed the Multi-Stage Smart Imaging Diagnostic Accelerator, winning the National Innovation Award — Clinical Innovation Award.
• Chung Shan Medical University Hospital (中山醫學大學附設醫院)majorStrategic or Co-development Partner · 1 August 2019MOU signed in August 2019 for joint development of smart medical systems and products. Chung Shan was the first hospital to order V5's AI Integration Platform and conducted clinical trials validating V5 Lung AI's effectiveness.

Scale indicators6 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• Optellum: UK-based AI company focused specifically on lung cancer screening and pulmonary nodule management, with FDA-cleared software that identifies at-risk nodules on CT. Most direct head-to-head competitor to V5 Lung AI in the LDCT lung cancer screening category.
• Lunit: Korean medical AI company with FDA-cleared Lunit INSIGHT CXR and CT products for chest and lung nodule detection. Comparable in lung cancer imaging AI focus, regulatory milestones, and global commercialization through distribution partners.
• Qure.ai: India-based AI radiology company with qCT product line for lung nodule detection and chest CT triage. Directly comparable AI chest CT capability, similar emerging-market-first international expansion playbook.
• Riverain Technologies (Siemens Healthineers): Developer of ClearRead CT, a leading AI solution for lung nodule detection on chest CT, now part of Siemens Healthineers. Direct competitor in pulmonary nodule detection accuracy and PACS-integrated clinical workflow.
• Annalise.ai: Australia-based medical imaging AI company offering comprehensive chest X-ray and CT AI including lung nodule and chest pathology detection. Comparable AI-augmented chest imaging offering for radiologists.
• Median Technologies: French company with LungSight and iCRO products for lung cancer imaging AI and oncology clinical trial imaging. Overlapping target use case (lung cancer imaging) with regulatory-grade clinical evidence focus.

Broad incumbents

• Aidoc: Israeli AI medical imaging company with broad CT triage and detection algorithms across multiple body parts. Competes with V5med in hospital AI orchestration but addresses a wider imaging portfolio beyond lung screening.
• Philips (IntelliSpace AI): Global medtech incumbent offering IntelliSpace AI including lung nodule detection and PACS-integrated clinical workflows. Larger incumbent with broader portfolio, deeper hospital relationships, and ability to bundle AI with imaging hardware sales.
• Siemens Healthineers (AI-Rad Companion): Major imaging equipment and software vendor with AI-Rad Companion Chest CT for lung nodule and pulmonary analysis. Largest peer by resources and global installed base, now also owning Riverain's ClearRead.

Emerging players

• Nanox (formerly Zebra Medical Vision): AI medical imaging company (with Zebra Medical Vision heritage) offering chest CT AI including lung analysis. Overlap with V5med in algorithmic lung CT analysis and emerging-player commercialization stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about V5med